Should health care systems and health care providers implement a new pathway for hospitalized patients with community-acquired pneumonia?

Archives of Internal Medicine

Volumn 172, Issue 22, 2012, Pages 1771-

  Carugati, Manuela ^a   Aliberti, Stefano ^b,c   Franzetti, Fabio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; ANTIBIOTIC THERAPY; CLINICAL PATHWAY; CLINICAL PRACTICE; COMMUNITY ACQUIRED PNEUMONIA; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MORTALITY; NOTE; PRIORITY JOURNAL; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; CRITICAL PATHWAYS; FEMALE; HUMANS; LENGTH OF STAY; MALE; PNEUMONIA, BACTERIAL;

EID: 84871378201     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/2013.jamainternmed.459     Document Type: Note

References (4)

1. Carratalà J, Garcia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med. 2012;172(12):922-928.
2. Sharpe BA. Putting a critical pathway into practice: the devil is in the implementation details. Arch Intern Med. 2012;172(12):928-929.
3. Garcia-Vidal C, Fernández-Sabé N, Carratalà J, et al. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J. 2008;32(3):733-739.
4. Aliberti S, Amir A, Peyrani P, et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest. 2008;134(5):955-962.